[go: up one dir, main page]

WO2012127483A1 - Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide - Google Patents

Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide Download PDF

Info

Publication number
WO2012127483A1
WO2012127483A1 PCT/IN2011/000203 IN2011000203W WO2012127483A1 WO 2012127483 A1 WO2012127483 A1 WO 2012127483A1 IN 2011000203 W IN2011000203 W IN 2011000203W WO 2012127483 A1 WO2012127483 A1 WO 2012127483A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
solvents
naphthyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000203
Other languages
French (fr)
Inventor
Dodda Mohan Rao
Pingili Krishna Reddy
Ambati Anna Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symed Labs Ltd
Original Assignee
Symed Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symed Labs Ltd filed Critical Symed Labs Ltd
Priority to PCT/IN2011/000203 priority Critical patent/WO2012127483A1/en
Priority to ARP110104215A priority patent/AR083841A1/en
Publication of WO2012127483A1 publication Critical patent/WO2012127483A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Definitions

  • the present invention relates to processes for the preparation of intermediates of N-[2-(7- methoxy-l-naphthyl) ethyl] acetamide.
  • Agomelatine is an agonist of melatoninergic system receptors and an antagonist of the 5-HT2C receptor. Those properties confer activity in the central nervous system and, more especially, in the treatment of severe depression, seasonal affective disorders, sleep disorders, cardiovascular pathologies, and pathologies of the digestive system, insomnia and fatigue resulting from jetlag, appetite disorders and obesity. Agomelatine is under regulatory review in US and is being approved in EU for the treatment of major depressive disorder. It is marketed under the trade names Valdoxan, Melitor, Thymanax in the form of tablets in dosage strength 25 mg. Agomelatine is chemically described as N-[2-(7-methoxy-l- naphthyl)ethyl]acetamide (herein after referred by generic name agomelatine) and is represented by the structural formula I
  • the processes of present invention are simple, eco-friendly, inexpensive, reproducible, and robust and feasible on an industrial scale.
  • the present invention relates to processes for the preparation of intermediates of N-[2-(7- methoxy-l-naphthyl) ethyl] acetamide (I).
  • the present invention relates to a process for the preparation of intermediate compound of formula II
  • X is halogen atom (F,C1, Br,I)
  • the present invention relates to isolated solid (7-Methoxy-l-naphthyl) ethanamine compound of structural formula VI as free base.
  • Fig. 1 is a schematic representation of the processes of the present invention.
  • the present invention is directed to processes for the preparation of intermediates of N-[2- (7-methoxy-l-naphthyl) ethyl] acetamide (I).
  • X is halogen atom (F,C1, Br,I)
  • the suitable aromatization reagents include but are not limited to quinone derivatives such as compounds of formula IV or V where X is halogen atom like F, CI, Br, and I which include DDQ, p-chloranil, p-bromanil, p-floranil, 2,3-dibromo-5,6-dicyano benzoquinone, 2,3- dicyano-4-chlorobenzoquinone, 2,3-dicyanobenzoquinone and other quinone derivatives such as 1,2-benzoquinones, 1,3-benzoquinones, o-chloranil, o-bromanil, o-floranil and the like or mixtures thereof, preferably DDQ or p-chloranil.
  • quinone derivatives such as compounds of formula IV or V where X is halogen atom like F, CI, Br, and I which include DDQ, p-chloranil, p-bromanil, p-f
  • the molar ratio of aromatization reagent to the compounds of formula (III) can be from about 5 : 1 to about 1 : 1 , preferably 1 : 1.
  • the organic solvents that can be used include but are not limited to halogenated solvents such as dichloromethane, ethylene dichloride, chloroform, chlorobenzene and the like; esters such as ethyl acetate, isopropyl acetate, tertiary butyl acetate and the like; hydrocarbon solvents such as n-hexane, n-heptane, cyclohexane, toluene, o-xylene, p-xylene and the like; ethers such as tetrahydrofuran, 1,4-dioxane, diethyl ether and the like; aprotic polar solvents such as ⁇ , ⁇ -dimethylformamide (DMF), dimethylsulfoxide (DMSO), N,N-dimethylacetamide (DMA), N-methyl pyrrolidone (NMP), ethylene glycol and the like; or mixtures thereof in various proportions without limitation.
  • the reaction is optionally performed in the absence of organic solvents.
  • the reaction temperature and the time should be suitable to bring the reaction to completion at a minimum time, without the production of unwanted side products. In general, it is convenient to carry out the reaction at a temperature of from about 35°C to about reflux temperatures of the solvents used. Preferably at reflux temperatures of the solvents used.
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagent and solvent employed. However, provided that the reaction is effected under the preferred conditions discussed above, a period from about 1 hour to about 15 hours, preferably from about 5 hour to 10 hours.
  • the desired compounds can be obtained from the reaction mixture by conventional means known in the art.
  • the working-up of reaction mixtures, especially in order to isolate desired compounds follows customary procedures, known to the organic chemists skilled in the norms of the art and steps, e.g. selected from the group comprising but not limited to extraction, neutralization, crystallization, chromatography, evaporation, drying, filtration, centrifugation and the like.
  • the intermediate compounds of formula II obtained by the process of present invention are optionally purified either by converting into respective acid addition salts or by recrystallization using the solvents or mixture of solvents or their aqueous mixtures or by slurry in the customary solvents.
  • the processes of present invention is of particular interest for the following reasons it allows the compound of formula (II), exclusively, to be obtained on an industrial scale.
  • This result is altogether surprising is due to the use of cheaper and simple reagents like DDQ and chloranil unlike palladium -carbon.
  • the rate of conversion of the compound of formula (III) to the compound of formula (II) is very high, exceeding 80%, unlike that which could be observed using palladium carbon, for which the rate does not exceed 75% whereas the use of quinone derivatives like DDQ or chloranil are entirely compatible with industrial requirements in terms of cost and the environment unlike hydrogenation catalyst for the conversion of the compound of formula (III) to the compound of formula (II) currently used.
  • it allows the compound of formula (II), exclusively, in particular free from the corresponding impurities.
  • the processes of present invention provides the compound of formula I from intermediate compound of formula II by using quinone derivatives of formula IV or V like DDQ or chloranil resulted in tremendous improvement in the yields and purities which ultimately lead to the higher yields and purities of final product.
  • the present process is very cost effective, reproducible and more viable on commercial scale.
  • the quinone derivatives described above can be recovered, recycled and reused thus making the process of present invention more economic.
  • the molar ratio of selenium to the compound of formula (III) can be from about 5:1 to about 1: 1, preferably 1 :1.
  • the reaction temperature and time when selenium is being used as reagent can be from about 100°C to about 250°C, preferably at a temperature of from about 215°C to about 220 °C.
  • the time required is from about 1 hour to about 10 hours, preferably from about 3 to 5 hours.
  • the processes of present invention described herein produces the intermediates and the final product in high yields and purities than the processes reported in the literature that too using simple and cost effective industrially applicable processes.
  • the isolated solid (7-Methoxy-l-naphthyI)ethanamine (VI) is pure. Preferably it has about 95% purity by weight with respect to other compounds. Preferably, the (7-Methoxy-l- naphthyl)ethanamine of formula VI is isolated in about 99% purity by weight. Thus, the isolated solid (7-Methoxy-l-naphthyl)ethanamine contains less than about 2%, preferably less than about 1 % by weight of impurities by HPLC.
  • the isolated solid (7-Methoxy-l-naphthyl)ethanamine (VI) of the present invention is prepared and isolated by the process substantially as described in example 9.
  • the solid 7-Methoxy-l-naphthyl)ethanamine (VI) is prepared either from its respective acid addition salt for example hydrochloric acid salt by using an organic or inorganic base in the presence of organic solvents or directly by free base using conventional techniques like crystallization from solvents or their mixtures or their aqueous mixtures thereof or by solvent- antisolvent technique.
  • the solvents that can be used for the isolation of compound of formula VI as solid include but are not limited alcohols such as methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutanol, and tertiary butyl alcohol and the like; halogenated solvents dichloromethane, ethylene dichloride, chloroform and the like; ketonic solvents such as acetone, methyl ethyl ketone, methyl isobutyl ketone, 2-butanone and the like; nitrile solvents such as acetonitrile, propionitrile and the like; esters such as ethyl acetate, isopropyl acetate and the like; hydrocarbons such as toluene, o-xylene, cyclohexane and the like or mixtures thereof in various proportions without limitation.
  • ethyl acetate ethyl acetate.
  • the antisolvents include, but are not limited to water, hydrocarbon solvents such as n- hexane, n-heptane, cyclohexane, petroleum ether, toluene and the like; ethers such as diethyl ether, diisopropyl ether, methyl tertiary butyl ether, and the like or mixtures thereof in various proportions without limitation.
  • hydrocarbon solvents such as n- hexane, n-heptane, cyclohexane, petroleum ether, toluene and the like
  • ethers such as diethyl ether, diisopropyl ether, methyl tertiary butyl ether, and the like or mixtures thereof in various proportions without limitation.
  • n-hexane Preferably n-hexane.
  • a solvent is any liquid substance capable of dissolving compound of VI or a salt thereof.
  • antisolvent means a liquid in which a compound is poorly soluble. The addition of an antisolvent to a solvent reduces the solubility of a compound.
  • a mixture of solvents refers to a composition comprising more than one solvent.
  • the isolated solid (7-Methoxy-l-naphthyl)ethanamine (VI) of the present invention is useful as a reference marker for agomelatine (I). As such, it may be used in order to detect the (7-Methoxy-l-naphthyl)ethanamine impurity in a agomelatine sample.
  • the starting intermediate compounds of formula III and the intermediate compound of formula VI can be prepared either by the processes reported in the art or by the process disclosed in our PCT application PCT/IN2011/000003.
  • the intermediate compounds of formula (II) obtained by the processes of present invention can be converted into final active compound agomelatine of formula I by processes described in the art. Illustratively, by the process described in U.S. Patent No. 7,544,839.
  • Exaniple-1 15 g. ( 0.07 mol) of (7-Methoxy-3,4-dihydro-l-naphthyl)acetonitrile, 24 g. (0.09 mol) of Chloranil (2,3,5,6-Tetrachlorocyclohexa-2,5-diene- 1 ,4-dione ) and 600 ml. of O-xylene were charged in a clean and dry 4 neck R.B. Flask and heated to reflux temperature for about 8 hrs. The resultant reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x50 ml of 10% w/v sodium hydroxide solution and 2x50 ml of water. The solvent was distilled completely under vacuum, the solid separated was recrystallized from ethanol and water mixture in 8:2 ratio to afford 13 g. (88%) of the title compound with a chemical purity 99%.
  • Example-2 The process is same as described in above example 1 by using toluene instead of o-xylene to yield 13.5 gr. (91%) of the title compound with a chemical purity 99%.
  • Example-3 5 g. (0.02 mol.) of (7-Methoxy-3,4-dihydro-l-naphthyl)acetonitrile, 7.5 g. (0.03 mol.) of 2,3-Dichloro-5,6-dicyano-benzoquinone (DDQ) and 200 ml. of O-xylene or toluene were charged in a clean and dry 4 neck R.B. Flask and heated to reflux temperature for about 2 hrs. The resultant reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x25 ml. of 10% w/v sodium hydroxide solution and 2x25 ml. of water.
  • DDQ 2,3-Dichloro-5,6-dicyano-benzoquinone
  • Example-4 5 g. (0.02 mol) of N-[2-(7-Methoxy-3,4-dihydro-l-naphthyl)ethyl]acetamide, 6 g. (0.03 mol.) of 2,3-Dichloro-5,6-dicyano-benzoquinone (DDQ) and 200 ml. O-xylene or toluene were charged in a clean and dry 4 neck R.B. Flask and heated to reflux temperature for about 4 hrs. The resultant reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x30 ml. of 10% w/v of sodium hydroxide solution and 2x30 ml. of water.
  • DDQ 2,3-Dichloro-5,6-dicyano-benzoquinone
  • Example-5 15 g. (0.06 mol) of N-[2-(7-Methoxy-3,4-dihydro-l-naphthyl)ethyl]acetamide, 19.5 g. (0.08 mol.) Chloranil (2,3,5,6-Tetrachlorocyclohexa-2,5-diene-l,4-dione ) and 600 ml. of O-xylene were charged in a clean and dry 4 neck R.B.Flask and heated to reflux temperature for about 5 hrs. The reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x50 ml. of 10%w/v sodium hydroxide solution and 3x50 ml.
  • Example-6 The process is same as described in above example 5 but using toluene instead of o-xylene to yield 13 g. (87%) of the title compound with a chemical purity exceeding 99%.
  • Example-7 Preparation of (7-Metboxy-l-naphthyl)acetonitrile using selenium
  • Example-8 Preparation of N-[2-(7-Methoxy-l-naphthyl)ethyl]acetamide using selenium lOg. (0.04mol.) of N-[2-(7-Methoxy-3,4-dihydro-l-naphthyl)ethyI]acetamide and 5 g. (0.06 mol.) of selenium metal powder were charged into a clean and dry 4 neck R.B.Flask and heated to about 220 °C for about 4 hrs. The resultant reaction mixture was allowed to reach about 65°C and extracted with 100 ml. of ethyl acetate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides processes for the preparation of intermediates of N-[2-(7-methoxy-1-naphthyl) ethyl] acetamide. More particularly the present invention relates to processes for the preparation of the compound of structural formula II. Also provides Isolated solid (7-Methoxy-l-naphthyl)ethanamine compound of structural formula VI as freebase.

Description

PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF N-[2-(7- METHOXY-1-NAPHTHYL) ETHYL] ACETAMIDE
BACKGROUND OF THE INVENTION
1. Technical field:
The present invention relates to processes for the preparation of intermediates of N-[2-(7- methoxy-l-naphthyl) ethyl] acetamide.
Brief description of the related art;
Agomelatine is an agonist of melatoninergic system receptors and an antagonist of the 5-HT2C receptor. Those properties confer activity in the central nervous system and, more especially, in the treatment of severe depression, seasonal affective disorders, sleep disorders, cardiovascular pathologies, and pathologies of the digestive system, insomnia and fatigue resulting from jetlag, appetite disorders and obesity. Agomelatine is under regulatory review in US and is being approved in EU for the treatment of major depressive disorder. It is marketed under the trade names Valdoxan, Melitor, Thymanax in the form of tablets in dosage strength 25 mg. Agomelatine is chemically described as N-[2-(7-methoxy-l- naphthyl)ethyl]acetamide (herein after referred by generic name agomelatine) and is represented by the structural formula I
Figure imgf000002_0001
More particularly the present invention relates to processes for the preparation of the compound of structural formula II
Figure imgf000002_0002
II
Where R is C= N, CH2-NH-COCH3 U.S.Patent No. 5,225,442 describes agomelatine, a pharmaceutical composition, a method of treatment, and a process for the preparation thereof.
US '442 disclose a process for the preparation of agomelatine which is illustrated by the below scheme:
Figure imgf000003_0001
Agomelatine
U.S.Patent No. US 7,544,839 describes the preparation of agomelatine as illustrated by below scheme :
Figure imgf000003_0002
(Agomelatine)
Aforementioned processes uses expensive reagents like palladium-carbon in addition to allyl compounds and involve prolong reaction time periods thus rendering the processes expensive and do not comply with industrial requirements in terms of cost and the environment. Hence, there is a need for an improved process for the preparation of intermediates of agomelatine , which can avoid the use of hazardous and expensive chemicals thus reducing the formation of process related impurities and related purification steps.
In view of the pharmaceutical value of this compound, it is important to be able to obtain by cost effective and simple processes that are readily amenable on industrial scale and that results in agomelatine in a good yield and with excellent purity.
The processes of present invention are simple, eco-friendly, inexpensive, reproducible, and robust and feasible on an industrial scale.
SUMMARY OF THE INVENTION
The present invention relates to processes for the preparation of intermediates of N-[2-(7- methoxy-l-naphthyl) ethyl] acetamide (I).
In one aspect, the present invention relates to a process for the preparation of intermediate compound of formula II
Figure imgf000004_0001
II
Where R is C= N, CH2-NH-COCH3
comprising:
subjecting the compound of formula III
Figure imgf000004_0002
III III
Where R is same as defined above
to aromatization by reacting with a quinone derivative of formula IV
Figure imgf000005_0001
Where X is halogen atom (F,C1, Br,I)
or formula V
Figure imgf000005_0002
V
Where X is same as defined above
or selenium metal to afford the compound of formula II.
In another aspect, the present invention relates to isolated solid (7-Methoxy-l-naphthyl) ethanamine compound of structural formula VI as free base.
Figure imgf000005_0003
VI
BRIEF DESCRIPTION OF THE DRAWING
Fig. 1: is a schematic representation of the processes of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to processes for the preparation of intermediates of N-[2- (7-methoxy-l-naphthyl) ethyl] acetamide (I).
In one embodiment of the present invention, there is provided a process for the preparation of intermediate compound of formula II
Figure imgf000006_0001
II
Where R is C= N, CH2-NH-COCH3
comprising:
subjecting the compound of formula III
Figure imgf000006_0002
in in
Where R is same as defined above
to aromatization by reacting with a quinone derivative of formula IV
Figure imgf000006_0003
IV
Where X is halogen atom (F,C1, Br,I)
or formula V
Figure imgf000006_0004
V
Where X is same as defined above
or selenium metal to afford the compound of formula II.
The suitable aromatization reagents include but are not limited to quinone derivatives such as compounds of formula IV or V where X is halogen atom like F, CI, Br, and I which include DDQ, p-chloranil, p-bromanil, p-floranil, 2,3-dibromo-5,6-dicyano benzoquinone, 2,3- dicyano-4-chlorobenzoquinone, 2,3-dicyanobenzoquinone and other quinone derivatives such as 1,2-benzoquinones, 1,3-benzoquinones, o-chloranil, o-bromanil, o-floranil and the like or mixtures thereof, preferably DDQ or p-chloranil.
The molar ratio of aromatization reagent to the compounds of formula (III) can be from about 5 : 1 to about 1 : 1 , preferably 1 : 1.
The organic solvents that can be used include but are not limited to halogenated solvents such as dichloromethane, ethylene dichloride, chloroform, chlorobenzene and the like; esters such as ethyl acetate, isopropyl acetate, tertiary butyl acetate and the like; hydrocarbon solvents such as n-hexane, n-heptane, cyclohexane, toluene, o-xylene, p-xylene and the like; ethers such as tetrahydrofuran, 1,4-dioxane, diethyl ether and the like; aprotic polar solvents such as Ν,Ν-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N,N-dimethylacetamide (DMA), N-methyl pyrrolidone (NMP), ethylene glycol and the like; or mixtures thereof in various proportions without limitation. Preferably the hydrocarbon solvent toluene or o-xylene is being used.
The reaction is optionally performed in the absence of organic solvents.
The reaction temperature and the time should be suitable to bring the reaction to completion at a minimum time, without the production of unwanted side products. In general, it is convenient to carry out the reaction at a temperature of from about 35°C to about reflux temperatures of the solvents used. Preferably at reflux temperatures of the solvents used. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagent and solvent employed. However, provided that the reaction is effected under the preferred conditions discussed above, a period from about 1 hour to about 15 hours, preferably from about 5 hour to 10 hours.
After completion of the reaction, the desired compounds can be obtained from the reaction mixture by conventional means known in the art. For example, the working-up of reaction mixtures, especially in order to isolate desired compounds, follows customary procedures, known to the organic chemists skilled in the norms of the art and steps, e.g. selected from the group comprising but not limited to extraction, neutralization, crystallization, chromatography, evaporation, drying, filtration, centrifugation and the like.
The intermediate compounds of formula II obtained by the process of present invention are optionally purified either by converting into respective acid addition salts or by recrystallization using the solvents or mixture of solvents or their aqueous mixtures or by slurry in the customary solvents.
Advantageously the processes of present invention is of particular interest for the following reasons it allows the compound of formula (II), exclusively, to be obtained on an industrial scale. This result is altogether surprising is due to the use of cheaper and simple reagents like DDQ and chloranil unlike palladium -carbon. The rate of conversion of the compound of formula (III) to the compound of formula (II) is very high, exceeding 80%, unlike that which could be observed using palladium carbon, for which the rate does not exceed 75% whereas the use of quinone derivatives like DDQ or chloranil are entirely compatible with industrial requirements in terms of cost and the environment unlike hydrogenation catalyst for the conversion of the compound of formula (III) to the compound of formula (II) currently used. Furthermore, it allows the compound of formula (II), exclusively, in particular free from the corresponding impurities.
Finally, the observed rates of conversion of the compounds of formula (III) to the compounds of formula (II) are high, exceeding 80%. hydrogenation of the compound using palladium-carbon or Raney nickel described in the prior art requires conditions that are difficult to apply on an industrial scale and the final yield is less than 70%. Furthermore, a principal drawback of that reaction is the concomitant formation of the "bis" compound and the difficulty of controlling the conversion rate of that impurity. The process developed by the Applicant allows the compounds of formula (II) to be obtained with a level of impurity down to below 1% under experimental conditions that are compatible with industrial requirements. The reported processes in the literature for the preparation of agomelatine or its intermediates results in the formation of various impurities and bye products leading to keep several purification steps intermittently at various stages thus resulting in very poor yields and purities of the intermediates and final product.
Advantageously, the processes of present invention provides the compound of formula I from intermediate compound of formula II by using quinone derivatives of formula IV or V like DDQ or chloranil resulted in tremendous improvement in the yields and purities which ultimately lead to the higher yields and purities of final product. Moreover the present process is very cost effective, reproducible and more viable on commercial scale.
Additionally the quinone derivatives described above can be recovered, recycled and reused thus making the process of present invention more economic. The molar ratio of selenium to the compound of formula (III) can be from about 5:1 to about 1: 1, preferably 1 :1.
The conversion of compound of formula III to the compound of formula II by aromatization using selenium is carried out in the absence of solvents and optionally in the presence of solvents as described above.
The reaction temperature and time when selenium is being used as reagent can be from about 100°C to about 250°C, preferably at a temperature of from about 215°C to about 220 °C. The time required is from about 1 hour to about 10 hours, preferably from about 3 to 5 hours.
Advantageously, the processes of present invention described herein produces the intermediates and the final product in high yields and purities than the processes reported in the literature that too using simple and cost effective industrially applicable processes.
In another embodiment of the present invention, there is provided isolated solid (7- Methoxy-l-naphthyl)ethanamine com ound of structural formula VI as free base.
Figure imgf000009_0001
VI
The isolated solid (7-Methoxy-l-naphthyI)ethanamine (VI) is pure. Preferably it has about 95% purity by weight with respect to other compounds. Preferably, the (7-Methoxy-l- naphthyl)ethanamine of formula VI is isolated in about 99% purity by weight. Thus, the isolated solid (7-Methoxy-l-naphthyl)ethanamine contains less than about 2%, preferably less than about 1 % by weight of impurities by HPLC.
The isolated solid (7-Methoxy-l-naphthyl)ethanamine (VI) of the present invention is prepared and isolated by the process substantially as described in example 9.
The solid 7-Methoxy-l-naphthyl)ethanamine (VI) is prepared either from its respective acid addition salt for example hydrochloric acid salt by using an organic or inorganic base in the presence of organic solvents or directly by free base using conventional techniques like crystallization from solvents or their mixtures or their aqueous mixtures thereof or by solvent- antisolvent technique.
The solvents that can be used for the isolation of compound of formula VI as solid include but are not limited alcohols such as methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutanol, and tertiary butyl alcohol and the like; halogenated solvents dichloromethane, ethylene dichloride, chloroform and the like; ketonic solvents such as acetone, methyl ethyl ketone, methyl isobutyl ketone, 2-butanone and the like; nitrile solvents such as acetonitrile, propionitrile and the like; esters such as ethyl acetate, isopropyl acetate and the like; hydrocarbons such as toluene, o-xylene, cyclohexane and the like or mixtures thereof in various proportions without limitation. Preferably, ethyl acetate.
The antisolvents include, but are not limited to water, hydrocarbon solvents such as n- hexane, n-heptane, cyclohexane, petroleum ether, toluene and the like; ethers such as diethyl ether, diisopropyl ether, methyl tertiary butyl ether, and the like or mixtures thereof in various proportions without limitation. Preferably n-hexane.
As used herein, a solvent is any liquid substance capable of dissolving compound of VI or a salt thereof.
As used herein, the term "antisolvent" means a liquid in which a compound is poorly soluble. The addition of an antisolvent to a solvent reduces the solubility of a compound.
As used herein a mixture of solvents refers to a composition comprising more than one solvent.
The isolated solid (7-Methoxy-l-naphthyl)ethanamine (VI) of the present invention is useful as a reference marker for agomelatine (I). As such, it may be used in order to detect the (7-Methoxy-l-naphthyl)ethanamine impurity in a agomelatine sample.
The starting intermediate compounds of formula III and the intermediate compound of formula VI can be prepared either by the processes reported in the art or by the process disclosed in our PCT application PCT/IN2011/000003.
The intermediate compounds of formula (II) obtained by the processes of present invention can be converted into final active compound agomelatine of formula I by processes described in the art. Illustratively, by the process described in U.S. Patent No. 7,544,839.
These processes are especially valuable for the following reasons: it makes it possible to obtain the compound of formula (I) in excellent yields on industrial scale.
The processes for the preparation of intermediates of agomelatine of the present invention is simple, eco-friendly, robust, reproducible, cost effective and well amenable on commercial scale. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES
Preparation of (7-Metho¾v-l-naphthyl)acetonitrile
Figure imgf000011_0001
Exaniple-1: 15 g. ( 0.07 mol) of (7-Methoxy-3,4-dihydro-l-naphthyl)acetonitrile, 24 g. (0.09 mol) of Chloranil (2,3,5,6-Tetrachlorocyclohexa-2,5-diene- 1 ,4-dione ) and 600 ml. of O-xylene were charged in a clean and dry 4 neck R.B. Flask and heated to reflux temperature for about 8 hrs. The resultant reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x50 ml of 10% w/v sodium hydroxide solution and 2x50 ml of water. The solvent was distilled completely under vacuum, the solid separated was recrystallized from ethanol and water mixture in 8:2 ratio to afford 13 g. (88%) of the title compound with a chemical purity 99%.
Example-2: The process is same as described in above example 1 by using toluene instead of o-xylene to yield 13.5 gr. (91%) of the title compound with a chemical purity 99%.
Example-3: 5 g. (0.02 mol.) of (7-Methoxy-3,4-dihydro-l-naphthyl)acetonitrile, 7.5 g. (0.03 mol.) of 2,3-Dichloro-5,6-dicyano-benzoquinone (DDQ) and 200 ml. of O-xylene or toluene were charged in a clean and dry 4 neck R.B. Flask and heated to reflux temperature for about 2 hrs. The resultant reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x25 ml. of 10% w/v sodium hydroxide solution and 2x25 ml. of water. The solvent was distilled completely under vacuum and the resulted solid residue was recrystallized from ethanol/ and water mixture in a ratio of 8:2 to yield 4.5 gr. (91%) of the title compound with a chemical purity 99%. Preparation of N-[2-(7-Methoxy-l-naphthyl) ethyljacetamide
Figure imgf000012_0001
Example-4: 5 g. (0.02 mol) of N-[2-(7-Methoxy-3,4-dihydro-l-naphthyl)ethyl]acetamide, 6 g. (0.03 mol.) of 2,3-Dichloro-5,6-dicyano-benzoquinone (DDQ) and 200 ml. O-xylene or toluene were charged in a clean and dry 4 neck R.B. Flask and heated to reflux temperature for about 4 hrs. The resultant reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x30 ml. of 10% w/v of sodium hydroxide solution and 2x30 ml. of water. After removal of the solvent by evaporation, the resultant solid residue was recrystallized from an ethyl acetate and n-hexane mixture in a ratio of 1 :2 to provide 4.5 g. (90%) of the title compound with a chemical purity exceeding 99%.
Example-5: 15 g. (0.06 mol) of N-[2-(7-Methoxy-3,4-dihydro-l-naphthyl)ethyl]acetamide, 19.5 g. (0.08 mol.) Chloranil (2,3,5,6-Tetrachlorocyclohexa-2,5-diene-l,4-dione ) and 600 ml. of O-xylene were charged in a clean and dry 4 neck R.B.Flask and heated to reflux temperature for about 5 hrs. The reaction mixture was cooled to about 30°C and filtered. The filtrate was washed with 3x50 ml. of 10%w/v sodium hydroxide solution and 3x50 ml. of water. The solvent was distilled completely under vacuum and the resultant solid residue was recrystallized from ethyl acetate and n-hexane mixture in 1 :2 ratio to yield 12 g. (81%) of the title compound with a chemical purity exceeding 99%.
Example-6: The process is same as described in above example 5 but using toluene instead of o-xylene to yield 13 g. (87%) of the title compound with a chemical purity exceeding 99%. Example-7: Preparation of (7-Metboxy-l-naphthyl)acetonitrile using selenium
lOg, (0.05 mol.) of (7-Methoxy-3,4-dihydro-l-naphthyl)acetonitrile and 6 g. (0.07 mol.) of selenium metal powder were charged into a clean and dry 4 neck R.B.Flask and heated to about 220 °C for about 3 hrs. The reaction mixture was allowed to reach about 65 °C and 30 ml. of water and ethanol mixture in ratio of 2: 8 was added. The resultant reaction mass was heated to reflux for 30 min. The hot reaction mixture was treated with 2 gr. of charcoal and filtered. The filtrate obtained was cooled to about 0°C for about 1 hr. The solid separated was filtered to obtain 6.5 g. (66%) of the title compound with a chemical purity 98%. Example-8: Preparation of N-[2-(7-Methoxy-l-naphthyl)ethyl]acetamide using selenium lOg. (0.04mol.) of N-[2-(7-Methoxy-3,4-dihydro-l-naphthyl)ethyI]acetamide and 5 g. (0.06 mol.) of selenium metal powder were charged into a clean and dry 4 neck R.B.Flask and heated to about 220 °C for about 4 hrs. The resultant reaction mixture was allowed to reach about 65°C and extracted with 100 ml. of ethyl acetate. The solvent was removed completely by evaporation, the solid residue obtained was recrystallized from a mixture of ethyl acetate and n-hexane in a ratio of 1 :2 to provide 6 gr. (61%) of the title compound with a chemical purity exceeding 99%.
Example-9: Preparation of (7-Methoxy-l-naphthyI)ethanamine in solid form
To 50g. (0.21 mol.) of (7-Methoxy-l-naphthyl) ethanamine hydrochloride solution in
250 ml. water present in a clean and dry R.B.Flask 5 gr. of charcoal was charged. The reaction mixture was stirred at about 30°C for about 15 min. and then filtered on a celite bed. Sodium carbonate (34 gr., 0.32 mol) was added to the filtrate obtained. Then the reaction mixture was stirred at about 30°C for about 15 min. and further cooled to about 10°C for about 30 min. The separated solid was filtered and the solid obtained was washed with 50 ml. of distilled water. 70 ml. of ethyl acetate was added to the wet solid and stirred at about 0 °C for about 30 min. The solid obtained was filtered and rinsed with ethyl acetate to afford 30 g. of the title compound.
M. R.: 101-104 °C. Purity by H.P.L.C: 99.85%.

Claims

We Claim:
1). A process for the preparation of i of II
Figure imgf000014_0001
II
Where R is C= N, CH2-NH-COCH3
comprising:
Figure imgf000014_0002
Where X is halogen atom (F,C1, Br,I)
or formula V
Figure imgf000014_0003
Where X is same as defined above
or using selenium metal to afford the compound of formula II. 2) The process of claim 1, wherein the aromatization reagents is selected from the group consisting of quinone derivatives of formula IV or V where X is halogen atom like F, CI, Br and I including DDQ, p-chloranil, p-bromanil, p-floranil, 2,3-dibromo-5,6-dicyano benzoquinone, 2,3-dicyano-4-chlorobenzoquinone, 2,3-dicyanobenzoquinone and other quinone derivatives like 1,2-benzoquinones, 1,3-benzoquinones, o-chloranil, o-floranil, o- bromanil or mixtures thereof, preferably DDQ or p-chloranil.
3) . The process of claim 1, wherein the organic solvent used is selected from the
group consisting of halogenated solvents like dichloromethane, ethylene dichloride, chloroform, chlorobenzene, esters like ethyl acetate, isopropyl acetate, tertiary butyl acetate, ethers like tetrahydrofiiran, 1,4-dioxane, diethyl ether, hydrocarbons like n-hexane, n-heptane, cyclohexane, toluene, o-xylene, p-xylene or mixtures thereof, aprotic polar solvents like Ν,Ν-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N,N- dimethylacetamide (DMA), N-methyl pyrrolidone (NMP), ethylene glycol or mixtures thereof, preferably toluene or o-xylene.
4). The process of claim 1, wherein the reaction is performed optionally in the absence of solvents when quinone derivatives are being used.
5). The process of claim 1, wherein the reaction is carried out at a temperature from about
50°C to about reflux temperatures of the solvents used and the time period is from about 1 hour to about 10 hours when quinone derivatives are being used.
6) The process of claim 1, wherein the conversion of compound of formula III to the
compound of formula II using selenium is carried out in the absence of solvents.
7) The process of claim 1 , wherein the reaction is carried out using selenium at a temperature from about 100°C to about 220°C and the time period is from about 1 hour to about 10 hours.
8) Isolated solid (7-Methoxy-l-naphthyl)ethanamine compound of structural formula VI as freebase
Figure imgf000015_0001
9). The process of claims 1 and 8, wherein the compounds are used as intermediates
preparation of active naphthalene derivatives like agomelatine (I).
PCT/IN2011/000203 2011-03-24 2011-03-24 Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide Ceased WO2012127483A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IN2011/000203 WO2012127483A1 (en) 2011-03-24 2011-03-24 Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide
ARP110104215A AR083841A1 (en) 2011-03-24 2011-11-11 PROCESSES FOR THE PREPARATION OF INTERMEDIARIES OF N- [2- (7-METOXI-1-NAFTIL) ETIL] ACETAMIDE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2011/000203 WO2012127483A1 (en) 2011-03-24 2011-03-24 Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide

Publications (1)

Publication Number Publication Date
WO2012127483A1 true WO2012127483A1 (en) 2012-09-27

Family

ID=46878711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000203 Ceased WO2012127483A1 (en) 2011-03-24 2011-03-24 Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide

Country Status (2)

Country Link
AR (1) AR083841A1 (en)
WO (1) WO2012127483A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113243A (en) * 2013-03-08 2013-05-22 山东方明药业集团股份有限公司 Synthetic method of 2-(7-methoxyl-1-naphthyl) ethylamine hydrochloride
WO2014072998A1 (en) * 2012-11-07 2014-05-15 Cadila Healthcare Limited An improved process for preparation of agomelatine
CN104130154A (en) * 2013-05-03 2014-11-05 郭炳华 Method for preparing high-purity agomelatine
CN113773221A (en) * 2021-10-08 2021-12-10 湖北工业大学 P-benzoquinone compound and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764635A (en) * 1986-08-14 1988-08-16 Ethyl Corporation Aromatization process
US6020513A (en) * 1996-08-29 2000-02-01 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US20050182276A1 (en) * 2004-02-13 2005-08-18 Jean-Claude Souvie Process for the synthesis and crystalline form of agomelatine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764635A (en) * 1986-08-14 1988-08-16 Ethyl Corporation Aromatization process
US6020513A (en) * 1996-08-29 2000-02-01 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US20050182276A1 (en) * 2004-02-13 2005-08-18 Jean-Claude Souvie Process for the synthesis and crystalline form of agomelatine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072998A1 (en) * 2012-11-07 2014-05-15 Cadila Healthcare Limited An improved process for preparation of agomelatine
CN103113243A (en) * 2013-03-08 2013-05-22 山东方明药业集团股份有限公司 Synthetic method of 2-(7-methoxyl-1-naphthyl) ethylamine hydrochloride
CN104130154A (en) * 2013-05-03 2014-11-05 郭炳华 Method for preparing high-purity agomelatine
CN113773221A (en) * 2021-10-08 2021-12-10 湖北工业大学 P-benzoquinone compound and preparation method thereof
CN113773221B (en) * 2021-10-08 2023-09-29 湖北工业大学 A kind of p-benzoquinone compound and preparation method thereof

Also Published As

Publication number Publication date
AR083841A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
JP5632279B2 (en) Preparation method and polymorph of ivabradine hydrochloride
JP5773874B2 (en) Method for preparing bendamustine
CN101421228B (en) Preparation of chiral amides and amines
AU2005200616A1 (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
EP2705023A1 (en) Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
US7705184B2 (en) Method of making amphetamine
KR102718536B1 (en) Process for preparing 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and its hydrogen sulfate salt
WO2009053545A2 (en) Novel method for the synthesis of (7-methoxy-l-naphthyl)acetonitrile and application in the synthesis of agomelatine
WO2012127483A1 (en) Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide
JP7116060B2 (en) R-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3(4H)-one Improved method for producing hydrochloride
JP5021004B2 (en) A novel method for synthesis of agomelatine
WO2013069025A1 (en) "process for the preparation of dexmedetomidine"
WO2014072998A1 (en) An improved process for preparation of agomelatine
US20120253051A1 (en) Process for the preparation of ropinirole and salts thereof
RU2791469C2 (en) Method for the preparation of 2-(5-methoxy isochroman-1-yl)-4,5-dihydro-1h-imidazole and its hydrosulfate
US7642279B2 (en) Atipamezole hydrochloride crystallization method
CN101489983B (en) Process for the preparation of optically active amines
US7728147B2 (en) Detomidine hydrochloride crystallization method
EP3247697A1 (en) Process and intermediates for the racemization of enantiomerically enriched 1-aminoindane
JP3144920B2 (en) α-Acylaminoketone derivatives, production method thereof and use thereof
WO2001019779A1 (en) Preparation of halogenated primary amines
CN103396360B (en) A kind of method preparing Primaquini Diphosphate
WO2008084499A1 (en) An industrial process for the preparation of pure ropinirole
HUE034889T2 (en) Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoyl-amino)benzyl]pyrimidin-5-yl]acetic acid
JP2006056832A (en) Method for producing and purifying 4-hydroxyquinolines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1331/CHENP/2012

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11861861

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11861861

Country of ref document: EP

Kind code of ref document: A1